Alcyone LifeSciences, Inc. logo

Alcyone LifeSciences, Inc.

Alcyone Lifesciences ?provides technology for neurosurgeons treat conditions in the central nervous system. Alcyone Lifesciences is a biotech medical device company focused on developing neural intervention systems and targeted drug delivery for chronic neurological conditions.

Feb 2018, Alcyone Lifesciences Completes Spin-Off of Hydrocephalus Business, Anuncia. Anuncia, Inc., patient-centric company solely focused on the treatment of Hydrocephalus, with ReFlow_ as its first product

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://alcyonels.com
Founded2010
Disease Focus
Development StagePreclinical
STOCK CODENon Listed
Address
250 Jackson St.Unit 494, Mill No. 5 BuildingLowell, MA 01852
Concord
United States
Email
Contact Number
+1 978-709-1946

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/alcyonelifesciences” connections=”true” suffix=””]

In Apr 2015, Alcyone MEMS Cannula (AMC_), a neuro-ventricular cannula, received FDA clearance. The AMC is a dual-lumen, MRI-compatible injection and aspiration cannula for use in the brain. The AMC is not intended for implant, and it is intended for single patient use only and can be utilized with any existing commercial imaging and stereotactic system. Neurosurgeons can select a target, navigate the AMC precisely to the target, and observe in real-time the precision delivery of the therapeutic agent, all under intra-procedural MRI guidance.

In May 201, Alcyone and DNAtrix entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyones MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrixs lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).

In Jul 2015, Lysogene S.A and Alcyone Lifesciences entered into a collaboration to evaluate the intraparenchymal delivery of Lysogenes proprietary rAAV based gene therapy to treat patients with Sanfilippo A, utilizing the Alcyone MEMS Cannula (AMC) targeted delivery platform.

Alcyone Lifesciences had received around $6.8 Mn USD in 3 rounds of investments lead by two investors: Edgar D. Jannotta, Jr. and Harbor Light Capital Partners.